[18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
Adenocarcinoma, Follicular
/ diagnostic imaging
Adult
Aged
Antineoplastic Agents
/ therapeutic use
Female
Fluorodeoxyglucose F18
Humans
Iodine Radioisotopes
Male
Middle Aged
Phenylurea Compounds
/ therapeutic use
Positron Emission Tomography Computed Tomography
Quinolines
/ therapeutic use
Survival Rate
Thyroid Neoplasms
/ diagnostic imaging
Tomography, X-Ray Computed
Treatment Outcome
Whole Body Imaging
[18F]-FDG-PET/CT
lenvatinib
metabolic response
radioiodine-refractory differentiated thyroid cancer
tyrosine kinase inhibitors
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
13 07 2021
13 07 2021
Historique:
received:
07
02
2021
pubmed:
27
4
2021
medline:
21
10
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
18F-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography ([18F]-FDG-PET/CT)-positive metastatic lesions in radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) have a poor prognosis and lenvatinib represents the best therapy. We investigated the role of [18F]-FDG-PET/CT in the evaluation of metabolic response and prediction of the outcome of RAI-R DTC patients treated with lenvatinib. Patients (n = 33) with progressive metastatic RAI-R DTC who were treated with lenvatinib were investigated at baseline and during follow-up with biochemical (thyroglobulin and thyroglobulin antibodies), morphological (whole-body CT scan) and metabolic ([18F]-FDG-PET/CT) evaluation. Nineteen (57.6%) patients showed the greatest metabolic response at the first [18F]-FDG-PET/CT scan, performed after 4 weeks of lenvatinib, while 5/33 (15.1%) patients had this response later. Moreover, 66.7% of patients had both a metabolic response at the first [18F]-FDG-PET/CT scan and a morphological response at the first CT scan. We observed a correlation between the metabolic response at [18F]-FDG-PET/CT scan performed after 4 weeks of treatment and the biochemical response at the same time in 60.6% of patients. The median overall survival (OS) was significantly longer in patients with either a metabolic response at last [18F]-FDG-PET/CT (40.00 vs 8.98 months) or a morphological response at last CT scan (37.22 vs 9.53 months) than in those without response. Moreover, the OS was longer in patients with a metabolic response at [18F]-FDG-PET/CT performed after 4 weeks of treatment (36.53 vs 11.28 months). Our data show that [18F]-FDG-PET/CT can early predict the response to lenvatinib and correlates with the OS of RAI-R DTC patients treated with this drug.
Identifiants
pubmed: 33901285
pii: 6253809
doi: 10.1210/clinem/dgab278
doi:
Substances chimiques
Antineoplastic Agents
0
Iodine Radioisotopes
0
Phenylurea Compounds
0
Quinolines
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
lenvatinib
EE083865G2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2355-2366Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.